University of Buffalo Clinical and Translational Science Institute

布法罗大学临床与转化科学研究所

• 批准号: 10516562
• 负责人: Timothy F Murphy
• 金额: $ 3.42万
• 依托单位: STATE UNIVERSITY OF NEW YORK AT BUFFALO
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-12 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10516562
• 关键词: Advertising; Area; Atherosclerosis; Award; Biometry; Biostatistics Core; Buffaloes; Center for Translational Science Activities; Cities; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Trials Design; Communication; Communities; Competence; Consultations; Core Facility; Data; Databases; Development; Diverse Workforce; Educational workshop; Environment; Experimental Designs; Flow Cytometry; Foundations; Funding; Future; Gender; Good Clinical Practice; Growth; Health; Health Care Research; Health Sciences; Healthcare; Healthcare Systems; Heart; Hispanic; Individual; Influentials; Institutes; Institution; Knowledge; Laboratories; Longevity; Medical; Medical Education; Mentors; Microscope; New York; Parents; Patients; Pediatric Hospitals; Population; Process; Public Health; Public Health Informatics; Recording of previous events; Reduce health disparities; Registries; Research; Research Design; Research Institute; Research Training; Schools; Science; Series; Special Population; Speed; Strategic Planning; Testing; Training; Translational Research; Translations; Underrepresented Minority; Universities; Vision; Work; Workforce Development; biomedical informatics; community engagement; digital; education research; endothelial dysfunction; epidemiology study; ethnic diversity; experience; experimental analysis; experimental study; health disparity; improved; informatics tool; innovation; laboratory facility; medical schools; multiple data sources; next generation; novel; novel strategies; recruit; response; responsible research conduct; skills; tool; translational pipeline; volunteer

CTSA UL1 Abstract The Buffalo Translational Consortium (BTC), which includes the University at Buffalo (UB) health sciences schools, the major healthcare institutions in our region, four key research institutes and five influential community partners, have embarked on a comprehensive strategic plan to build a strong foundation for clinical and translational research in response to our community needs. Buffalo is the second most populous city in New York State and has a rich cultural history. The proportion of underrepresented minorities in Buffalo in 2018 (50%) parallels that projected for the US in 2050, making Buffalo a microcosm of what the US will look like in 30 years. A similar proportion of our population experiences health disparities. The vision for our CTSA hub is to perform innovative research across the translational spectrum to improve the health of our community and the nation. We will develop, test and share novel approaches to engage difficult-to-engage populations and reduce health disparities in our community, which represents a “population of the future”. Guided by our vision, the CTSA has catalyzed a transformation of our environment since our CTSA was first funded in August 2015 with remarkable growth in clinical and translational research. Further, in just the past year, the UB medical school has moved into a spectacular new building and our clinical partner, Kaleida Health, the largest healthcare system in the region, opened the new Oishei Children’s Hospital, both on the Buffalo Niagara Medical Campus and connected to the Clinical and Translational Research Center devoted entirely to clinical and translational research that opened in 2012. This rapid and continuing trajectory of growth in healthcare and research in the region has resulted in a new 21st century Academic Health Center with healthcare, medical education and clinical and translational research on one campus in the heart of Buffalo, creating a foundation to enhance the impact of our CTSA even further. While launching our CTSA, we have prioritized participation in the national consortium through hosting and testing Innovation Labs as a team science tool, working with multiple hubs on initiatives to solve translational research barriers and sharing tools that we have developed with the CTSA consortium, including novel health informatics tools. Our CTSA has five ambitious but achievable aims, including: 1) Accelerate innovative translational research with teams that engage communities, regional stakeholders and the national consortium; 2) Train an excellent, diverse workforce to advance translation of discoveries; 3) Enhance inclusion of special populations across the lifespan and difficult-to-engage populations; 4) Streamline clinical research processes focusing on quality and efficiency with emphasis on multisite studies; 5) Develop, test and share biomedical informatics tools to integrate data from multiple sources to speed translation. Guided by our vision to perform research to improve the health of our community and the nation, we will continue our momentum to expand translational research, train our diverse workforce, streamline processes, engage our community, and actively contribute to the national consortium. CTSA Diversity Supplement: Bacterial Derived Aortic Endothelial Dysfunction to Promote Atherosclerosis Dayron Leya Rodriquez, the candidate for this diversity supplement is of Hispanic background and completion of this supplement award will allow him to gain academic knowledge, research skills and professional development in the areas of clinical and translational research. This proposal encompasses aims of the parent CTSA UL1 award to 1) train an excellent diverse workforce to advance translational and health-related research with 2) ehnanced inclusion of special populations. To complete the proposed supplemental research, Dayron will utilize the following CTSA cores: • Biostatistics, Epidemiology and Research Design (BERD) Core: Dayron will leverage the expertise and support of his mentor Dr. Greg Wilding (Director of BERD), for appropriate statistical experimental design and analysis of all experimental data. He will also complete the BERD Statistical workshops and BERD Clinical Trials workshops series to gain competency in aspects applicable to clinical and translational research. • Workforce Development Core: Dayron will complete workshop series (each containing 4-8 individual workshops) in the areas of a) Responsible Conduct of Research, b) Scientific Communication, c) Translational Teamwork and d) Good Clinical Practice. Following completion of each series, Dayron will be awarded a Digital Badge and with completion of all these workshops will earn his CTSI Basic Micro-credential in Clinical and Translational Reseach. • Cinical Research Facilitation Core: Dayron and our research team will work with faciltators to continue successful recruitment strategies including flyers and advertising as well as access to patient databases such as the Buffalo Research Registry to recruit local volunteers. Consultation with the Community Engagement Core will facilitate appropriate community recruitment of subjects from both genders and diverse ethnic backgrounds to increase the robustness of our subject population and collected data. • Laboratory Facility Cores. Dayron will utilize the Confocal Microscope and Flow Cytometry Facility and Next Generation Seqeuncing and Expression Facility for completion of the proposed experiments.

CTSA UL1 摘要 布法罗翻译联盟 (BTC)，其中包括布法罗大学 (UB) 健康科学系 学校、本地区主要医疗机构、四个重点研究机构和五个有影响力的社区 合作伙伴已开始制定全面的战略计划，为临床和 响应我们社区需求的转化研究。布法罗是新州人口第二多的城市 约克州拥有丰富的文化历史。 2018 年布法罗代表性不足的少数族裔比例 (50%) 与 2050 年美国的预测类似，布法罗成为美国 30 年后的缩影。 我们有类似比例的人口经历着健康差异。我们 CTSA 中心的愿景是执行 跨转化领域的创新研究，以改善我们社区和国家的健康。 我们将开发、测试和分享新方法来吸引难以参与的人群并降低健康水平 我们代表“未来人口”的社区存在差异。在我们的愿景指导下，CTSA 已 自 2015 年 8 月首次资助 CTSA 以来，我们的环境发生了显着的转变 临床和转化研究的增长。此外，就在过去的一年里，布法罗大学医学院搬进了 一座壮观的新建筑和我们的临床合作伙伴 Kaleida Health，该地区最大的医疗保健系统， 新的 Oishei 儿童医院在布法罗尼亚加拉医学园区开业，并与 临床和转化研究中心完全致力于临床和转化研究，于 2012年。该地区医疗保健和研究的快速持续增长导致了 全新 21 世纪学术健康中心，提供医疗保健、医学教育以及临床和转化服务 在布法罗市中心的一个校区进行研究，为增强我们 CTSA 的影响奠定了基础 更远。在启动我们的 CTSA 时，我们优先通过主办国家联盟来参与 并测试创新实验室作为团队科学工具，与多个中心合作解决转化问题 我们与 CTSA 联盟开发的研究障碍和共享工具，包括新型健康 信息学工具。我们的 CTSA 有五个雄心勃勃但可实现的目标，包括： 1) 加速创新 与社区、区域利益相关者和国家联盟参与的团队进行转化研究； 2) 培养一支优秀、多元化的员工队伍，以推进发现的转化； 3）加强特殊包容性 整个生命周期的人群和难以参与的人群； 4) 简化临床研究流程 注重质量和效率，强调多地点研究； 5) 开发、测试和分享生物医学 信息学工具可集成多个来源的数据以加快翻译速度。以我们的愿景为指导来执行 研究以改善我们社区和国家的健康，我们将继续扩大发展势头 转化研究，培训我们多元化的员工队伍，简化流程，参与我们的社区，并积极 为国家财团做出贡献。 CTSA 多样性补充：细菌源性主动脉内皮功能障碍促进动脉粥样硬化 Dayron Leya Rodriquez，这个多元化补充的候选人有西班牙裔背景和完成度 该补充奖将使他获得学术知识、研究技能和专业知识 临床和转化研究领域的发展。该提案包含了家长的目标 CTSA UL1 奖项旨在 1) 培养优秀的多元化员工队伍，以推进转化和健康相关研究 2) 加强特殊人群的包容性。 为了完成拟议的补充研究，Dayron 将利用以下 CTSA 核心： • 生物统计学、流行病学和研究设计 (BERD) 核心：Dayron 将利用专业知识 以及他的导师 Greg Wilding 博士（BERD 主任）的支持，以进行适当的统计实验设计 并对所有实验数据进行分析。他还将完成 BERD 统计研讨会和 BERD 临床研讨会 试验研讨会系列，以获得适用于临床和转化研究方面的能力。 • 劳动力发展核心：Dayron 将完成研讨会系列（每个研讨会包含 4-8 名个人） 研讨会）在以下领域：a）负责任的研究行为，b）科学传播，c）转化 团队合作和 d) 良好临床实践。 完成每个系列后，Dayron 将获得数字徽章，并完成所有这些 研讨会将为他赢得临床和转化研究方面的 CTSI 基本微型证书。 • 临床研究促进核心：Dayron 和我们的研究团队将与促进者合作，继续 成功的招募策略，包括传单和广告以及访问患者数据库，例如 作为布法罗研究登记处招募当地志愿者。咨询社区参与 核心将促进适当的社区招募来自性别和不同种族的受试者 背景以提高我们的受试者群体和收集的数据的稳健性。 • 实验室设施核心。 Dayron 将利用共焦显微镜和流式细胞术设备 用于完成拟议实验的下一代测序和表达设施。